The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma

Abstract

Background Inhibition of Serum Amyloid A-like 1 (SAAL1) expression could inhibit cancer progression and improve the prognosis of cancer patients. At present, the correlation between SAAL1 and lung adenocarcinoma (LAC) remains unclear. Therefore, this study surveyed the worth and pathway of SAAL1 in LAC progression and immunity. Methods Bioinformatics and immunohistochemistry were used to identify the SAAL1 expression in LAC. The roles of SAAL1 expression in the existence values of LAC patients were explored, and the nomograms were constructed. Clinical values of SAAL1 co-expressed genes were evaluated by COX regression, survival, and Receiver operating characteristic (ROC) analysis. EDU and western blotting methods were used to inquiry the functions and pathways of the SAAL1 in cell growths. The correlation between the SAAL1 level and immune microenvironment was visualized using correlation research. Results SAAL1 level was elevated in LAC tissues, and was observed in cancer tissues of dead patients. SAAL1 overexpression had something to do with shorter overall survival, progression-free interval, and disease-specific survival in LAC. The area under the curve of SAAL1 was 0.902 in normal tissues and cancer tissues. Inhibition of SAAL1 expression could inhibit cancer cell proliferation, which may be related to the decreased expression of cyclin D1 and Bcl-2 proteins. In LAC, SAAL1 level had something to do with stromal, immune, and estimate scores, and correlated with macrophages, T cells, Th2 cells, CD8 T cells, NK CD56dim cells, DC, eosinophils, NK CD56bright cells, pDC, iDC, cytotoxic cells, Tgd, aDC cells, B cells, Tcm, and TFH levels. SAAL1 overexpression had something to do with existence values and the immunity in LAC. Conclusions Inhibition of SAAL1 expression could regulate cancer growth via cyclin D1 and Bcl-2. SAAL1 is a promising prognostic biomarker in LAC patients.

Comprehensive expression, prognostic and validation analysis of necroptosis-related lncRNAs in esophageal cancer

“…The expression level of lncRNA ENSG00000253385.1 significantly differed between TFH and NK CD56dim cells. In lung cancer studies, SAAL1 levels are also correlated with the numbers of NK CD56dim cells and TFH cells[ 44 ]. These abnormally infiltrated immune cells may be involved in tumor initiation and development.…”

Downregulation of DIP2B as a prognostic marker inhibited cancer proliferation and migration and was associated with immune infiltration in lung adenocarcinoma via CCND1 and MMP2

“…DAB staining was applied, followed by restaining with hematoxylin. The slides were then washed and mounted [ 10 ]. Finally, the stained tissues were observed and analyzed under a microscope, and the images were recorded.…”

“…Finally, the stained tissues were observed and analyzed under a microscope, and the images were recorded. In addition, the standard process of immunoblotting was followed to detect the expression level of DIP2B in LUAD, and the DIP2B antibody (863713, ZENBIO, China) concentration was 1:1000 [ 10 ].…”